

Stephen E Spurgeon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2376540/publications.pdf>

Version: 2024-02-01

30
papers

877
citations

623734

14
h-index

477307

29
g-index

30
all docs

30
docs citations

30
times ranked

1442
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase 1 study of the PI3K \hat{I} inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). <i>Blood</i> , 2014, 123, 3398-3405.	1.4	245
2	Survival trends in mantle cell lymphoma in the United States over 16 years 1992â€“2007. <i>Leukemia and Lymphoma</i> , 2012, 53, 1488-1493.	1.3	73
3	Targeting BCL-2 and ABL/LYN in Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia. <i>Science Translational Medicine</i> , 2016, 8, 354ra114.	12.4	65
4	Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 \hat{I} , In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 1777-1777.	1.4	54
5	Cladribine: not just another purine analogue?. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1169-1181.	4.1	51
6	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	1.4	50
7	The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 378-387.	2.5	40
8	Aberrations of MYC Are a Common Event in B-Cell Prolymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2014, 142, 347-354.	0.7	40
9	Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1488-1494.	1.3	39
10	Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. <i>Oncotarget</i> , 2018, 9, 24576-24589.	1.8	36
11	Improved survival in hairy cell leukaemia over three decades: a <scp>SEER</scp> database analysis of prognostic factors. <i>British Journal of Haematology</i> , 2013, 163, 407-409.	2.5	32
12	Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110 \hat{I} Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies.. <i>Blood</i> , 2009, 114, 922-922.	1.4	24
13	CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. <i>Leukemia Research</i> , 2017, 53, 39-49.	0.8	22
14	Phase 1â€“2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed Bâ€“cell nonâ€“Hodgkin lymphoma and previously untreated mantle cell lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 845-854.	2.5	18
15	Concurrent STAT3, DNMT3A, and TET2 mutations in Tâ€“LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential. <i>American Journal of Hematology</i> , 2017, 92, E6-E8.	4.1	16
16	Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 1207-1211.	5.2	12
17	Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw263.	6.3	10
18	Chronic lymphocytic leukemia with a FGFR3 translocation: case report and literature review of an uncommon cytogenetic event. <i>Cancer Genetics</i> , 2014, 207, 340-343.	0.4	6

#	ARTICLE	IF	CITATIONS
19	Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome. <i>Leukemia Research Reports</i> , 2015, 4, 8-11.	0.4	6
20	Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2258-2260.	1.3	6
21	Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA7502-LBA7502.	1.6	6
22	MYD88 mutation analysis of a rare composite chronic lymphocyte leukemia and lymphoplasmacytic lymphoma by flow cytometry cell sorting. <i>Annals of Hematology</i> , 2015, 94, 1941-1944.	1.8	5
23	Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia. <i>Case Reports in Hematology</i> , 2022, 2022, 1-5.	0.4	5
24	A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2011, 118, 441-441.	1.4	4
25	Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 716-721.	1.3	3
26	Combined Epigenetic and Immunotherapy For Newly Diagnosed Mantle Cell Lymphoma: Correlative Studies Suggest The Importance Of Enhanced ADCC, Mechanisms of Resistance and Cyclin D1 Nuclear Localization Genotype. <i>Blood</i> , 2013, 122, 3063-3063.	1.4	3
27	Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report. <i>American Journal of Case Reports</i> , 2017, 18, 516-519.	0.8	3
28	A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2021, 106, 294-297.	2.2	2
29	A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2023, 64, 722-724.	1.3	1
30	The First Report of Endoscopic Ultrasound-guided Intralesional Rituximab in a Patient With Mantle Cell Lymphoma Presenting With Isolated Colorectal Involvement. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e485-e487.	0.4	0